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Abstract   
Dysfunctional fatty acid (FA) metabolism plays an important role in the pathogenesis of -cell 
dysfunction and loss of -cell mass in type 2 diabetes (T2D). The elongation of very long chain 
fatty acid family member 6 (Elovl6) regulates the elongation of C12–16 saturated and 
monounsaturated FAs. To define the role of Elovl6 in T2D development, we assessed the effects 
of Elovl6 deletion in leptin receptor-deficient db/db mice in a model of T2D. db/db mice with 
the Elovl6 deletion had a markedly increased -cell mass, hyperinsulinemia, and improved 
glycemic control. Increased -cell mass was associated with decreased islet oleate levels and 
protection from islet inflammation. We also observed a significant increase in chemokine (C-C 
motif) ligand 2 (Ccl2) expression and secretion in response to oleate in MIN6 cells. Data 
suggested that Elovl6 was a fundamental factor linking dysregulated lipid metabolism to -cell 
dysfunction and islet inflammation in T2D. 
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Introduction 
The increasing prevalence of obesity worldwide has become an alarming public health concern 
because of dramatic increases in the incidence of obesity-associated diseases, including type 2 
diabetes (T2D) 
1, 2
. Obesity leads to progressive deterioration of the insulin secretory function of 
pancreatic  cells and reduced capacity to compensate for increased peripheral insulin resistance 
3, 4
. Both -cell dysfunction and actual decrease in -cell mass were implicated in the 
deterioration of functional -cell capacity.   
Lipid accumulation in non-adipose tissues, a phenomenon known as lipotoxicity, was 
implicated in both pathologies as a molecular link between obesity and dysregulated glucose 
homeostasis 
5
. Pancreatic  cells are highly susceptible to lipotoxicity, and both exogenous and 
endogenous sources of fatty acids (FAs) are believed to be involved in functional deterioration 
of  cells 6. Numerous studies showed that saturated FAs (SFAs) such as palmitate (C16:0) 
suppressed insulin gene expression and secretion and ultimately induced -cell apoptosis and/or 
dedifferentiation through multiple processes, including generation of ceramides and reactive 
oxygen species (ROS), endoplasmic reticulum (ER) stress, and inflammation 
7,
 
8,
 
9,
 
10,
 
11,
 
12
. 
Monounsaturated FAs (MUFAs), such as palmioleate (C16:1n-7) and oleate (C18:1n-9), and the 
polyunsaturated FA (PUFA) eicosapentaenoate (C20:5n-3) can protect  cells from apoptosis 
and insulin secretory defects induced by SFAs 
9,
 
13,
 
14
. In addition to exogenous FA composition, 
6 
 
evidence indicates that the intracellular capacity to modulate FA composition of lipid species 
might be another determinant of -cell lipotoxicity. FA desaturase and elongase enzymes modify 
FAs by adding a cis-double bond or two carbons, respectively, to fatty acyl-CoA 
15,
 
16
. These 
reactions are essential for a variety of cellular functions, including maintenance of membrane 
FA composition and generation of signaling molecules. However, unique roles for these 
enzymes in pancreatic  cells remain to be defined.  
The elongation of very long-chain fatty acid (ELOVL) family member Elovl6 is a 
microsomal enzyme involved in the elongation of saturated and monounsaturated FAs with 12, 
14, and 16 carbons 
17,
 
18
. Loss of Elovl6 function reduces stearate (C18:0) and oleate (C18:1n-9) 
levels and increases palmitate (C16:0) and palmitoleate (C16:1n-7) levels 
19,
 
20
.  In our 
previous study, we reported that mice with the targeted disruption of Elovl6 (Elovl6
−/−
) were 
protected against the development of hepatic insulin resistance and deterioration of insulin 
secretory function of pancreatic  cells in animals fed a high-fat and high-sucrose diet, despite 
similar levels of hepatosteatosis and obesity between Elovl6-deficient and wild-type mice 
19,
 
21
. 
These findings suggested that the vital role of alterations in FA composition by Elovl6 
deficiency extended beyond lipid accumulation and impacted insulin sensitivity and -cell 
function. Therefore, Elovl6 inhibition could be a potential therapeutic approach in T2D 
treatment. A critical question that needs to be answered is whether inhibition of this elongase 
7 
 
confers reduced susceptibility to T2D. In the present study, we investigated the effects of Elovl6 
deletion in leptin receptor-deficient Lepr
db/db
 (db/db) mice in a model of T2D 
22
. 
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Methods 
Animals. All animal husbandry and animal experiments complied with the guidelines of the 
University of Tsukuba’s regulations of animal experiments and were approved by the Animal 
Experiment Committee of the University of Tsukuba. Elovl6
−/−
 mice on C57BL6J background 
were generated as described previously 
19
. We obtained Lepr
db/+
 (db/+) mice on a C57BL/KsJ 
background from Charles River Japan and crossed with Elovl6
−/−
 mice to obtain db/+;Elovl6
+/−
 
mice. db/+;Elovl6
+/−
 mice were then crossed more than seven generations into the C57BL/KsJ 
background. Finally, double heterozygous male and female mice were bred to generate mice 
with the double mutation of Lepr and Elovl6 (db/db;Elovl6
−/−. All animals were housed in a 
pathogen-free barrier facility with a 12-h light/dark cycle and were given free access to normal 
chow and water. Age- and sex-matched littermates were used for all experiments, and mice were 
sacrificed during the light phase after food deprivation for 4 h. Plasma samples were collected 
by retro-orbital bleeding. Tissues were isolated immediately to be weighed and stored in liquid 
nitrogen. 
 
Blood chemistry. Enzymatic assays for glucose, triglycerides (TG), total cholesterol (T-Cho), 
and free fatty acids (FFA) levels were measured with colorimetry test kits purchased from Wako 
Pure Chemical Industries (Osaka, Japan). Plasma insulin levels were determined using a mouse 
9 
 
insulin ELISA kit (Shibayagi, Gunma, Japan) according to the manufacturer’s protocol. HbA1c 
was measured using an HbA1c immunoassay kit (DCA2000 system; Bayer Medical, Tokyo, 
Japan). For oral glucose tolerance test (OGTT), mice were orally administrated D-glucose (1 
g/kg body weight) after an overnight fast (16 h). For insulin tolerance test (ITT), mice were 
injected intraperitoneally with human regular insulin (Eli Lilly). Blood samples were collected 
before injection and at specific times after injection (indicated in figures) to determine glucose 
and insulin levels. 
 
Islet morphology and immunohistochemistry. Pancreases were excised, fixed in 10% neutral 
buffered formalin, embedded in paraffin, and cut into 4-m-thick sections for hematoxylin and 
eosin (H&E) staining. Insulin- and glucagon-containing cells were identified by 
immunofluorescence staining using a guinea pig anti-human insulin antibody (Dako Japan, 
Tokyo, Japan) with FITC-conjugated goat anti-guinea pig secondary antibody (Santa Cruz 
Biotechnology, Dallas, TX) and a rabbit anti-glucagon antibody (Dako) with Alexa Fluor 
555-conjugated goat anti-rabbit secondary antibody (Santa Cruz Biotechnology), as described 
previously  
21
. For continuous BrdU labeling in mice, BrdU was diluted in drinking water to a 
concentration of 1.0 mg/ml and administered for consumption ad libitum for 5 days. Pancreatic 
tissue was harvested and processed as described above for immunohistochemistry. Sections 
10 
 
were stained with an anti-BrdU antibody (Abcam, Cambridge, UK). TUNEL staining was 
performed using DeadEnd
TM
 Fluorometric TUNEL system (Promega, Madison, WI). All images 
were acquired using a BZ-X710 microscope (Keyence, Japan), and data were analyzed using a 
BZ-H3 analyzer (Keyence, Japan) and Adobe Photoshop
®
 software (Adobe Systems, San Jose, 
CA).  
 
Isolation of mouse pancreatic islets. Isolation of islets from mice was performed by 
Ficoll-Conray density-gradient centrifugation 
35,
 
36,
 
21
. Briefly, 2.5 ml of 0.4 mg/ml liberaze 
enzyme brends (Liberase TL Research Grade, Roche Diagnostics) was injected into the 
pancreatic duct and incubated in 1ml of 1.0 mg/ml liberaze enzyme brends at 37 °C for 20 min.  
The islets were subsequently purified by ficoll gradient and hand picking. 
 
Analysis of insulin secretion and insulin content of islets. Insulin secretion and insulin 
content of the islets were measured as previously described 
35,
 
36,
 
21
. Isolated islets were 
incubated for 2 h in RPMI-1640 medium supplemented with 10% FBS, 100 U/ml penicillin, and 
100 mg/ml streptomycin. 5 islets of similar size for each condition were preincubated for 30 
min in 2.8 mM glucose in 1% BSA Krebs-Ringer Bicarbonate Hepes (KRBH) buffer.  Finally, 
they were incubated in 2.8 mM glucose, 20 mM glucose, or 2.8 mM glucose with 30 mM KCl 
11 
 
in 1% BSA KRBH buffer for 30 min, or total islet insulin extraction by 0.5 ml cold acid ethanol 
mixture (75% ethanol with 0.2 mol/l HCl), and insulin secretion was analyzed using a mouse 
insulin ELISA kit (Shibayagi, Gunma, Japan). Hoechst-33258 was used to determine the DNA 
contents of sonicated islets. 
 
Determination of TG content and FA composition of islets. For TG determination, total lipids 
were extracted from isolated islets (100 islets/sample) by the Folch method, followed by 
measurement with a GPO-Trinder kit (Sigma, St. Louis, MO) 
35,
 
21
. For determination of FA 
composition, total lipids were extracted from isolated islets (400 islets/sample) using the 
Bligh-Dyer’s method 21. Lipid fractions in samples were methyl-esterified, and the relative 
abundance of each FA was quantified by gas chromatography as described previously 
19
. 
 
Cell culture and treatment. Mouse insulinoma MIN6 cells were cultured as described 
previously 
37
. Palmitate (C16:0) and oleate (C18:1n-9) were dissolved to 100 mM in ethanol to 
prepare stock solutions, which were then diluted in DMEM supplemented with 0.5% BSA to a 
final concentration of 200 μM. MIN6 cells were treated for 24 h, and cell viability was 
determined by 3-(4,5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide (MTT) assay. 
Apoptosis was determined by immunohistochemistry to cleaved caspase-3 (Cell Signaling 
12 
 
Technology Japan). Secreted CCL2 levels in cell culture supernatants were determined by 
ELISA according to the manufacture’s protocol (R&D Systems, Minneapolis, MN). The stained 
samples were observed using fluorescence microscope (Keyence BZ – X710).  
 
RNA extraction and quantitative real-time PCR. Total RNA extraction from freshly isolated 
islets and cells, cDNA synthesis, and quantitative real-time PCR (RT-PCR) were performed as 
previously described 
38
. Primer sequences for Ins1, Ins2, Gcg, Pdgfra, Reg3a, Reg3b, Reg2, 
Ccr2, Ccl21a, Glycam1, Saa3, Xbp1s, Ddit3, Hspa5, and Casp1 are presented in Table 1. Other 
qPCR primers used were described previously 
21, 35, 36, 38, 39
. mRNA expression levels were 
normalized to that of cyclophilin mRNA for all experiments. 
 
Statistical analysis. Values were expressed as means ± SEM and analyzed using ANOVA. 
Differences were considered significant for P <0.05. 
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Results 
1. Elovl6 deficiency in db/db mice improves hyperglycemia and glucose intolerance. 
In order to investigate the role of Elovl6 in T2D development and progression, we first 
determined the effect of endogenous Elovl6 in leptin receptor-deficient db/db mice, which 
exhibit obesity, insulin resistance, and resultant -cell failure as a model of T2D, generating 
Elovl6-deficient db/db mice (db/db;Elovl6
−/−
). During 6–16 weeks of age both db/db;Elovl6+/+ 
and db/db;Elovl6
−/−
 mice gained body weight (BW) without any significant differences. At 40 
weeks of age when emergence of diabetes caused BW loss in db/db;Elovl6
+/+
 mice, 
db/db;Elovl6
−/−
 mice still sustained a gain with significant difference as compared to 
db/db;Elovl6
+/+
 mice. There was no significant difference in food intake between the two 
genotypes (4.5  0.5 g/day in db/db;Elovl6+/+ mice versus 4.7  0.1 g/day in db/db;Elovl6−/− 
mice). Surprisingly, although obesity in db/db mice was not improved, Elovl6 deficiency 
markedly improved hyperglycemia (Fig. 1b) and showed hyperinsulinemia (Fig. 1c) in db/db 
mice. These metabolic changes also manifested in HbA1c levels in db/db;Elovl6
−/−
 mice that 
were almost normalized (Fig. 1d). Furthermore, improved plasma glucose clearance (Fig. 2a) 
and increased insulin secretion (Fig. 2b) were observed in db/db;Elovl6
−/−
 mice by oral glucose 
tolerance test (OGTT), whereas insulin sensitivity as evidenced by insulin tolerance test (ITT) 
did not differ between two genotypes (Fig. 2c, d). db/db;Elovl6
+/−
 mice did not show any 
14 
 
improvement of hypeglycemia, plasma insulin levels and HbA1c levels (data not shown), 
suggesting complete loss of Elovl6 is necessary to prevent the progression of T2D of db/db 
mice. These results suggested that Elovl6 deficiency prevented T2D progression by increasing 
insulin secretory capacity of pancreatic  cells in db/db mice. 
As development of hepatosteatosis, adipocyte inflammation, and hyperlipidemia 
accompanied by the obesity model with pancreatic -dysfunction and glucose intolerance, we 
weighed liver and epididymal white adipose tissue (eWAT) and measured metabolic parameters. 
Liver weight and hepatic triglyceride (TG), total cholesterol (T-Cho) content and alanine 
transaminase (ALT) levels were higher, whereas plasma levels of TG and free FA (FFA) were 
lower in db/db;Elovl6
−/−
 mice than in db/db;Elovl6
+/+
 mice (Table 2). Analysis of liver 
histology further confirmed the dramatic increase in lipid droplets in db/db;Elovl6
−/−
 mice 
compared with db/db;Elovl6
+/+
 mice (Fig. 3a), suggesting the possibility that the 
over-accumulation of lipids in liver canceled the beneficial effects of the changes of hepatic FA 
composition by Elovl6 deficiency on insulin sensitivity 
19, 41, 42
. Hepatic gene expression analysis 
showed a consistent increase in glucokinase (Gck) and stearoyl-CoA desaturase 1 (Scd1) 
expression in db/db;Elovl6
−/−
 mice, indicating increased glycolysis and lipogenesis (Fig. 3b). 
Additionally, Elovl6 deficiency reduced glucose-6-phosphatase (G6pc) mRNA levels in db/db 
mice, consistent with a reduction in blood glucose levels (Fig. 3b). Elovl6 deficiency in db/db 
15 
 
mice did not improve adipocyte size or adipose tissue inflammation. Histological examination 
of eWAT sections revealed adipocyte hypertrophy in both db/db;Elovl6
+/+
 and db/db;Elovl6
−/−
 
mice (Fig. 4a). Real-time PCR analysis showed that expression levels of lipogenic and 
proinflammatory genes in the eWAT of db/db;Elovl6
+/+
 and db/db;Elovl6
−/−
 mice were similar 
(Fig. 4b). These results demonstrated that amelioration of T2D progression by Elovl6 deficiency 
in db/db mice was not attributed to altered lipid accumulation and inflammation, or improved 
insulin resistance in liver and WAT.  
 
2. Elovl6 deficiency expands -cell mass in pancreatic islets of db/db mice. 
Pancreatic islets isolated from db/db;Elovl6
−/−
 mice were morphologically compared with those 
from db/+;Elovl6
+/+
, db/+;Elovl6
−/−
, and db/db;Elovl6
+/+
 mice. Both the number (Fig. 5a) and 
size (Fig. 5b) of islets were greater in db/db;Elovl6
−/−
 mice than in db/db;Elovl6
+/+
 mice. 
Histological examination indicated that the islets in db/db;Elovl6
−/−
 mice were markedly 
enlarged compared with those in db/db;Elovl6
+/+
 mice (Fig. 5c). Immunostaining of pancreatic 
sections from 16-week-old animals with antibodies to insulin and glucagon revealed that Elovl6 
deficiency in db/db mice resulted in a significant increase in -cell mass, whereas -cell mass 
was smaller in db/db mice than in db/+;Elovl6
+/+
 mice (Fig. 5d and Fig. 6). In contrast, we did 
not detect any apparent differences in scattered  cell distribution between db/db;Elovl6+/+ and 
16 
 
db/db;Elovl6
−/−
 mice, indicating no change in dedifferentiation (Fig. 5d).   
To elucidate how Elovl6 deletion may expand -cell mass, we studied -cell 
proliferation and apoptosis. To evaluate -cell proliferation, mice were administered BrdU. The 
number of BrdU-positive cells was approximately 2.5-fold greater in islets from db/db;Elovl6
−/−
 
mice than in those from db/db;Elovl6
+/+
 mice (Fig. 5e). TUNEL staining demonstrated that 
-cell apoptosis was about 4.3-fold greater in db/db;Elovl6+/+ mice than in db/+;Elovl6+/+ mice 
(Fig. 5f). Elovl6 deletion, however, dramatically reduced -cell apoptosis in db/db mice to 
levels observed in db/+;Elovl6
+/+and db/+;Elovl6−/− mice. Therefore, islet hyperplasia in 
db/db;Elovl6

 mice was a consequence of both increased proliferation and reduced apoptosis 
of  cells. 
 
3. Elovl6 deficiency improves -cell function in pancreatic islets of db/db mice. 
To evaluate the effects of Elovl6 deficiency on insulin secretion ex vivo, pancreatic islets were 
isolated from db/+;Elovl6
+/+
, db/+;Elovl6
−/−
, db/db;Elovl6
+/+
, and db/db;Elovl6
−/−
 mice. Insulin 
secretion from db/db;Elovl6
+/+
 islets in response to high glucose was blunted (Fig. 7a). Elovl6 
deficiency enhanced glucose-stimulated insulin secretion (GSIS) in both db/+ and db/db islets. 
Elovl6 deficiency also enhanced KCl-stimulated insulin secretion in both db/+ and db/db islets. 
Compared with db/+;Elovl6
+/+
 islets, insulin content of db/db;Elovl6
+/+
 islet was significantly 
17 
 
decreased (Fig. 7b). Conversely, insulin content was higher in db/db;Elovl6
−/−
 islets than in 
islets from db/+;Elovl6
+/+
, db/+;Elovl6
−/−
, and db/db;Elovl6
+/+
 mice (Fig. 7b). These results 
suggested that Elovl6 deficiency improved impaired GSIS from db/db;Elovl6
−/−
 islets by 
improving -cell function and increased islet size and number, which contributed to 
improvement of glucose intolerance observed in db/db mice. 
 
4. Elovl6 deficiency alters fatty acid composition in the islets of db/db mice. 
Because excessive TG accumulation in pancreatic  cells is known to be associated with 
lipotoxicity and reduces insulin secretion, we further determined TG content of islets isolated 
from db/+;Elovl6
+/+
, db/+;Elovl6
−/−
, db/db;Elovl6
+/+
, and db/db;Elovl6
−/−
 mice (Fig. 7c). The 
TG content of db/+;Elovl6
−/−
 islets were indistinguishable from that of the db/+;Elovl6
+/+
 islets. 
The TG content was markedly higher in db/db;Elovl6
+/+
 islets than in db/+;Elovl6
−/−
 and 
db/+;Elovl6
+/+
 islets and was prevented by Elovl6 deficiency. 
To further estimate the impact of diabetic state and Elovl6 deficiency on FA profile in 
pancreatic islets, we analyzed the FA composition of islets isolated from db/+;Elovl6
+/+
, 
db/+;Elovl6
−/−
, db/db;Elovl6
+/+
, and db/db;Elovl6
−/−
 mice (Fig. 7d). There were no significant 
differences in FA composition between db/+;Elovl6
+/+
 and db/+;Elovl6
−/−
 mice. Compared with 
db/+;Elovl6
+/+
 mice, the islet FA composition in db/db;Elovl6
+/+
 mice showed a significant 
18 
 
decrease in stearate (C18:0) and an increase in palmitoleate (C16:1n-7) and oleate (C18:1n-9) 
FA composition. Compared with db/db;Elovl6
+/+
 islets, there was a marked reduction in oleate 
composition of db/db;Elovl6
−/−
 islets, which was similar to that observed in db/+;Elovl6
+/+
 and 
db/+;Elovl6
−/−
 controls. The relative amounts of palmitate was tend to increase and palmitoleate 
was significantly increased in db/db;Elovl6
−/−
 islets compared with db/db;Elovl6
+/+
 islets. The 
ratio of MUFAs in db/db;Elovl6
−/−
 islets was consistently lower than that in db/db;Elovl6
+/+
 
islets (Fig. 7d). We also analyzed the plasma FA composition of db/+;Elovl6
+/+
, db/+;Elovl6
−/−
, 
db/db;Elovl6
+/+
, and db/db;Elovl6
−/−
 mice (Fig. 8). We found that the changes in plasma FA 
composition resulting from Elovl6 deletion in db/db mice were different from those in islets: 
db/db;Elovl6
−/−
 mice had decreased levels of stearate and oleate and increased levels of 
palmitate and palmitoleate in plasma. These results suggested that the modulation of 
intracellular FA composition in  cells by Elovl6 was associated with-cell dysfunction and that 
Elovl6 deficiency could play a positive role in -cell mass and function through reduction of 
oleate and TG content under diabetic conditions. 
 
5. Elovl6 deficiency reduces expression of inflammatory genes in pancreatic islets of db/db 
mice. 
To provide insight into how Elovl6 deficiency might alter gene expression profile to preserve 
19 
 
-cell function and mass, we analyzed isolated islets for genes encoding proteins with functions 
in FA and glucose metabolism, insulin production, cell proliferation, apoptosis, inflammation, 
and ER stress (Fig. 9). Expression levels of lipogenic genes, including Elovl6, Scd1, and Scd2, 
were significantly lower in db/db;Elovl6
+/+
 islets than in control db/+;Elovl6
+/+
 islets (Fig. 9a). 
Expression levels of Scd1 and Scd2 were similarly decreased in db/db;Elovl6
−/−
 islets, whereas 
there was a tendency to decrease in the expression of sterol regulatory element binding protein 
1c (Srebf1c) and its target gene uncoupling protein-2 (Ucp2) in db/db;Elovl6
−/−
 islets compared 
with db/db;Elovl6
+/+
 islets. Expression of peroxisome proliferator activated receptor  (Ppara), 
a key regulator of FA oxidation, was elevated similarly in both db/db;Elovl6
+/+
 and 
db/db;Elovl6
−/−
 islets (Fig. 9b). However, expression levels of Ppar target genes involved in 
-oxidation such as carnitine palmitoyltransferase 1a (Cpt1a) and acyl-Coenzyme A 
dehydrogenase, medium chain (Acadm) were significantly decreased in db/db;Elovl6
−/−
 islets 
compared with db/db;Elovl6
+/+
 islets, suggesting the difference in TG accumulation between 
db/db;Elovl6
+/+
 islet and db/db;Elovl6
−/−
 islet was not due to the difference in the capacity for 
islet FA oxidation. Expression levels of master transcription factors regulating insulin gene 
expression and GSIS in mature  cells such as pancreatic and duodenal homeobox factor 1 
(Pdx1), musculoaponeurotic fibrosarcoma oncogene family A (MafA), and neurogenic 
differentiation 1 (Neurod1) as well as insulin 1 (Ins1), insulin 2 (Ins2), and synaptotagmin-like 4 
20 
 
(Sytl4), a crucial component of the insulin secretion, were coordinately repressed in 
db/db;Elovl6
+/+
 islets compared with those in db/+;Elovl6
+/+
 islets (Fig. 9c). Conversely, 
expression of these genes were significantly restored in db/db;Elovl6
−/−
 islets than in 
db/db;Elovl6
+/+
 islets. While, the expression level of neurogenin 3 (Neurog3), the islet-defining 
factor, is similar in all groups. Expression levels of glucose transporter 2 (Slc2a2), Gck, and 
insulin receptor substrate 2 (Irs2), genes important for glucose metabolism and -cell mass 
expansion, were similar between db/db;Elovl6
+/+
 and db/db;Elovl6
−/−
 islets (Fig. 9c). 
Expression levels of genes involved in -cell proliferation and islet regeneration such as platelet 
derived growth factor receptor, alpha polypeptide (Pdgfra), regenerating islet-derived 3 alpha 
(Reg3a), Reg3b, and Reg2 were markedly higher in db/db;Elovl6
+/+
 islets than in db/+;Elovl6
+/+
 
islets (Fig. 9d). Expression levels of these genes were significantly decreased in db/db;Elovl6
−/−
 
islets compared with db/db;Elovl6
+/+
 islets. Expression levels of apoptosis-related genes such as 
B cell leukemia/lymphoma 2 (Bcl2) and BCL2-associated X protein (Bax) were similar in all 
groups (Fig. 9e). However, Elovl6 deficiency significantly decreased the expression of caspase 1 
(Casp1), a gene involved in inflammation and cell death, in both db/+ and db/db islets. The 
effect of the Elovl6 deficiency on the inflammatory gene expression in the islet of db/db mice 
was striking. Expression levels of the macrophage marker CD68 antigen (Cd68), inflammatory 
cytokine and its receptor such as tumor necrosis factor  (Tnf), interleukin 1 beta (Il1), 
21 
 
chemokine (C-C motif) ligand 2 (Ccl2), chemokine (C-C motif) receptor 2 (Ccr2), chemokine 
(C-C motif) ligand 21A (Ccl21a), the L-selectin ligand glycosylation-dependent cell adhesion 
molecule 1 (Glycam1), and the acute phase protein serum amyloid A 3 (Saa3) were higher in 
db/db;Elovl6
+/+
 islets than in control db/+;Elovl6
+/+
 islets (Fig. 9f). However, Elovl6 deficiency 
significantly decreased the expression of these proinflammatory genes in both db/+ and db/db 
islets. In db/db;Elovl6
+/+
 mice, the expression of activating transcription factor 3 (Atf3), a 
stress-inducible transcription factor with a complex central role in modulating pro-inflammatory 
responses, was dramatically increased in db/db;Elovl6
+/+
 islets (Fig. 9g). Strikingly, the 
expression of Atf3 was markedly suppressed in db/db;Elovl6
−/−
 islets than in db/db;Elovl6
+/+
 
islets. Expression of the spliced form of X-box binding protein 1 (Xbp1s), which controls the 
development and maintenance of ER, was significantly decreased in db/db;Elovl6
+/+
 islets yet 
was maintained in islets from db/db;Elovl6
−/−
 mice (Fig. 9g). In contrast, the expression levels 
of genes for unfolded protein response (UPR) such as DNA-damage inducible transcript 3 
(Ddit3) and heat shock protein 5 (Hspa5) were similar between db/db;Elovl6
+/+
 and 
db/db;Elovl6
−/−
 islets. Decreased pancreatic islet inflammation in db/db;Elovl6
−/−
 mice was 
further examined by immunohistochemistry (Fig. 10), which showed that the number of 
infiltrating Mac3-positive macrophages was markedly greater in db/db;Elovl6
+/+
 mice than in 
db/+;Elovl6
+/+
 mice, whereas macrophage infiltration was protected in pancreatic islets of 
22 
 
db/db;Elovl6
−/−
 mice. Together, these results indicated that Elovl6 regulated both -cell mass 
and insulin production potentially thorough modulation of islet inflammation under diabetic 
conditions.  
 
6. Oleate induces -cell dysfunction and inflammation in MIN6 cells. 
High FA levels in -cell have been associated with decline in -cell function and mass in T2D, 
in particular in combination with high glucose levels 
3
. To examine the physiological relevance 
of decreased oleate levels in db/db;Elovl6
−/−
 islets (Fig.7d), we next determined whether -cell 
function and islet inflammation could be altered by changes in cellular FAs regulated by Elovl6. 
MIN6 cells were cultured in medium supplemented with FAs for 24 h. Consistent with many 
previous studies, palmitate dramatically reduced viability and increased apoptosis in MIN6 cells 
(Fig. 11a, b). Meanwhile, oleate also led to a significant decrease in cell viability and a mild 
increase in apoptosis. Next, the effect of Elovl6-related FAs on mRNA expression in MIN6 cells 
was determined. As expected, MIN6 cells treated with palmitate exhibited downregulation of 
Pdx1 and upregulation of Ccl2, Atf3, and carnitine palmitoyltransferase 1a (Cpt1a) compared 
with control cells, indicating -cell lipotoxicity was induced by palmitate (Fig. 11c). 
Interestingly, similar expression changes were also seen in cells treated with palmitoleate and 
stearate. However, cells treated with oleate had similar or greater changes in the expression of 
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these genes than cells treated with other FAs: Decreased Pdx1 expression and increased Atf3 and 
Cpt1a expression were greater with oleate treatment than with palmitate exposure. Ccl2 
expression and CCL2 secretion was significantly increased by both palmitate and oleate to 
similar extents (Fig. 11c, d). The data suggested that palmitate and oleate both cause similar 
cellular stress responses, but distinct consequences, presumably due to different pathways for 
apoptosis in a short term. These results showed that in vivo, the cellular oleate content could be 
a determinant of Elovl6-mediated -cell function and suggested that the FA composition of 
islets in db/db;Elovl6
−/−
 mice was favorable for the protection of  cells in db/db mice. 
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Discussion 
In the present study, we demonstrated that Elovl6 deletion in db/db mice significantly reduced 
circulating blood glucose levels without affecting obesity or insulin resistance. We observed that, 
compared with db/db;Elovl6
+/+
 mice, db/db;Elovl6
−/−
 mice had improved glucose tolerance, 
enhanced GSIS, hyperinsulinemia, and markedly increased -cell mass associated with 
increased proliferation and decreased apoptosis. Molecular mechanisms underlying these 
phenotypic changes in db/db;Elovl6
−/−
 mice involve decreased expression of islet 
proinflammatory genes and attenuated islet inflammation accompanied with decreased islet 
oleate and TG levels (Fig 12). Our findings indicated that Elovl6-mediated modulation of 
intracellular FA metabolism in  cells was essential in preventing the toxic effects of FAs and 
preserving proper -cell function, which might contribute to the expansion of -cell mass in 
obesity. 
Elucidation of the factors triggering islet inflammation in T2D is of emerging 
importance. Previous studies demonstrated that macrophage recruitment and inflammation in 
pancreatic islets played a key role in -cell dysfunction in patients with T2D and animal T2D 
models including diet-induced obese C57BL/6J and db/db mice and GK rats 
23,
 
24,
 
25
. Our 
findings demonstrated that Elovl6 deletion ameliorated pancreatic islet inflammation in db/db 
mice, supported by decreased expression of genes with inflammatory function, i.e. Casp1, Tnf, 
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Ccl2, Ccr2, and Atf3, by mRNA analysis and decreased Mac3-positive cells in islets by 
immunohistochemical analysis in mice with Elovl6 deletion. Whether macrophage infiltration 
causes T2D islet pathology requires further investigation. However, during disease progression, 
macrophages may play a role in accelerating pancreatic islet cell dysfunction and death. Thus, 
improved inflammation observed in db/db;Elovl6
−/−
 islets could underlie the prevention of 
-cell failure and the development of diabetes caused by insulin resistance and obesity. 
 cells respond to endogenous stimuli, including FAs, by initiating macrophage 
recruitment via production of chemokines, and subsequent interactions between  cells and 
macrophages perpetuate inflammatory processes within islets that lead to -cell dysfunction 3, 26, 
25
. Importantly, db/db;Elovl6
−/−
 islets displayed a marked reduction in oleate and MUFA content 
without increasing SFA, compared with db/db;Elovl6
+/+
 islets. Most studies thus far have 
focused on SFAs to which many lipotoxic effects are attributed 
7,
 
10,
 
11,
 
12
. The role of MUFAs is 
less studied and more controversial. Oleate, the most common MUFA in cells and plasma, was 
not cytoprotective; however, oleate-induced apoptosis was less than that induced by SFAs in 
INS-1E and MIN6 insulinoma cell lines 
27, 28
. Meanwhile, oleate-induced -cell dysfunction was 
observed in -cell lines and pancreatic islets that exhibited impaired GSIS following oleate 
exposure 
29, 30, 31
. Bush et al. performed a microarray analysis of palmitate- and oleate-exposed 
MIN6 cells and found that the expression of proinflammatory genes encoding chemokines and 
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mediators of acute phase response were increased by both FAs 
26
. In line with these previous 
reports, we confirmed that oleate contributed to -cell dysfunction and initiated inflammatory 
processes within islets: Oleate-treated MIN6 cells were dysfunctional, with decreased Pdx1 
expression and increased Ccl2 expression and CCL2 secretion accompanied with mild apoptosis. 
These effects were also comparable with palmitate-induced dysfunction in MIN6 cells. The 
combination of oleate with high glucose worsens -cell function and death by cytokine 
production and promotion of inflammation, accompanied with the production of harmful side 
products, suggesting that oleate induced reciprocal interactions between  cells and 
macrophages, at least in part via cytokines, further augmenting macrophage recruitment and 
-cell dysfunction (Fig 12). Although MIN6 cells are widely used to study the mechanism of 
GSIS in -cell 40, it does not retain physiological response to glucose. Therefore, it is an ideal if 
we can use primary cultured  cells for analyzing the role of Elovl6 in  cell. 
It remains to be determined whether the effect of oleate on inflammation is mediated 
by oleate itself or via intermediate products of oleate metabolism. The underlying mechanism of 
oleate-associated toxic effects in  cells remains unknown, but Elovl6-mediated compositional 
changes in specific FAs may impact cellular functions important for T2D development. Previous 
studies showed that lipid accumulation and TG content in pancreatic islets were associated with 
impaired -cell secretory capacity and dysfunction 5, 6. A potential mechanism of reduction in 
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islet TG in db/db;Elovl6
−/−
 mice is suppression of TG synthesis secondary to decreased oleate 
levels in the islets (Fig 12). Because oleate is a good substrate for diacylglycerol acyltransferase, 
the rate-limiting step in TG synthesis, excessive TG accumulation with oleate might contribute 
to -cell dysfunction and islet inflammation. We previously observed SREBP-1c suppression in 
the liver of Elovl6
−/−
 mice, but not in pancreatic islets in the current study. The inhibition of 
conversion from palmitate to stearate resulting in reduction in oleate levels in  cells is likely a 
major contributor to decreased islet TG content and resolved inflammation in the current study.  
Our results support the hypothesis that Elovl6 deletion protects against -cell failure in 
db/db mice as a genetic model of T2D. However, as Elovl6 deletion was not targeted to pancreas 
and was achieved in all tissues, the possibility remains that Elovl6 deletion might affect the FA 
profile in other tissues to impact overall organismal metabolism and, therefore, cell function. 
Indeed, we previously showed that Elovl6 deficiency altered FA composition in serum and 
various organs and affected a wide range of cellular functions and the disease progression 
19, 21, 
32, 33, 34
. Our findings demonstrated that Elovl6 deletion in db/db mice decreased stearate and 
oleate levels while increasing palmitate and palmitoleate levels in plasma. We assume these 
changes in plasma FA composition might influence the FA composition of islets; however, 
changes in FA composition of db/db;Elovl6
−/−
 islets were different from changes observed in 
plasma: a marked reduction in oleate component without a reduction in stearate and an increase 
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in palmitate, compared with db/db;Elovl6
+/+
 islets. Thus, these results suggested that the 
Elovl6-regulated FA chain elongation from C16 to C18 and subsequent SCD-mediated C18 
desaturation in  cells were essential for maintaining proper function and preventing the toxic 
effects of Fas (Fig 12). Further analysis on lipidomics of islet and plasma samples of 
db/+;Elovl6
+/+
, db/+;Elovl6
−/−
, db/db;Elovl6
+/+
, and db/db;Elovl6
−/−
 mice could provide 
potential insight into the relationship between exogenous and endogenous FA supply in islets 
and its role in T2D. As a consequence of the greater steatosis observed in db/db;Elovl6
−/−
 mice, 
a more efficient FA storage could reduce -cell lipotoxicity. Since chronic exposure to elevated 
FFA levels were shown to impair pancreatic -cell function in T2D patients3, 4, improving FA 
sequestration could improve -cell function. While we could not rule out the potential effects of 
Elovl6 in other cell types in the current study, the observed protective effects of Elovl6 deletion 
on lipotoxicity in db/db islets and the proinflammatory effect of oleate in MIN6 cells indicated 
that Elovl6 expression in  cell might play a key role in pancreatic -cell failure in T2D. MIN6 
cells are widely used as a useful model for studying the mechanism of glucose-stimulated 
insulin secretion in pancreatic  cells. However, it is not necessarily a normal glucose response 
model, but the ideal is if primary  cells could be used for the physiological function analysis of 
 cells. Future studies in mice with conditional deletion of Elovl6 in pancreatic  cells and other 
cell types are necessary to further delineate its role in T2D. Our message is at least tissue FA 
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composition involving C16 and C18 modified by endogenous Elovl6 activity have a marked 
impact on -cell mass and function, but it is an important question regarding clinical strategy for 
T2D whether exogenous FAs mimicking the FA composition of Elovl6
−/−
 mice would have 
similar favorable effects.  
In summary, we provided evidence showing the beneficial effect of Elovl6 loss in 
db/db mice supporting previously not fully appreciated- -cell toxic effect of oleate. The results 
of the current study, combined with our previous findings demonstrating that Elovl6 deficiency 
improved peripheral insulin resistance induced by a high-fat diet, suggested that limiting Elovl6 
expression or activity in individuals during early diabetes or in those with metabolic syndrome 
might be beneficial for T2D prevention and treatment. 
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Table 1. Sequence information for the quantitative real-time PCR analysis 
 
Gene 
name 
Forward primer 
(5’ to 3’) 
Reverse primer 
(5’ to 3’) 
Ins1 GAAGTGGAGGACCCACAAGTG CTGAAGGTCCCCGGGGCT 
Ins2 TGCTGATGCCCTGGCCTGCTCT CTGGTCCCACATATGCACATGCA 
Gcg ACTCACAGGGCACATTCACC CATCATGACGTTTGGCAATG 
Pdgfra CTGGCATGATGGTCGATTCT GACTTCACTGGTGGCATGGT 
Reg3a TGCTCTCCTGCCTGTTGTTT TGGGAGCGATAAGCCTTGTA 
Reg3b CCCAGGCTTATGGCTCCTAC GTGTCCTCCAGGCCTCTTTT 
Reg2 CACTGCCAACCGTGGTTAT GACAAAGGAGTACTGTGCCTCA 
Casp1 CGTACACGTCTTGCCCTCAT ATCCTCCAGCAACTTCA 
Ccr2 GGGAGACAGCAGATCGAGTG GCATTAGCTTCAGATTTACGGGT 
Ccl21a GTGATGGAGGGGGTCAGGA GGGATGGGACAGCCTAAACT 
Glycam1 GAATCAAGAGGCCAGGATG TCCTCCACTGTCTGGCTTGA 
Saa3 AGCCAAAGATGGGTCCAGTT TCAGAGTAGGCTCGCCACAT 
Xbp1s CTGAGTCCGAATCAGGTGCAG GTCCATGGGAAGATGTTCTGG 
Ddit3 TCCCTAGCTTGGCTGACAGA TCCTCCTGGGCCATAGAACT 
Hspa5 TTCAGCCAATTATCAGCAAACTC
T 
TTTTCTGATGTATCCTCTTCACCA
GT 
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Table 2. Phenotypic comparison of db/+;Elovl6
+/+
, db/+;Elovl6
−/−
, db/db;Elovl6
+/+
, and 
db/db;Elovl6
−/−
 mice at 16 weeks of age. 
 
 
 
db/+;Elovl6
+/+
(n = 8) 
db/+;Elovl6
−/−
(n = 10) 
db/db;Elovl6
+/+ 
(n = 11) 
db/db;Elovl6
−/−
(n = 13) 
Body weight 
(g) 
32.1 ± 0.8 27.1 ± 0.8 50.6 ± 1.6 51.3 ± 1.0 
Liver weight 
(% BW) 
3.5 ± 0.1 3.9 ± 0.1 ## 6.1 ± 0.5 8.9 ± 0.2 *** 
eWAT weight 
(%BW) 
2.1 ± 0.1 2.0 ± 0.2 5.1 ± 0.3 4.2 ± 0.2 ** 
Fasting plasma 
glucose (mg/dl) 
65.4 ± 5.3 57.3 ± 7.8 470.2 ± 35.4 204.5 ± 13.5 *** 
Refed plasma 
glucose (mg/dl) 
195.2 ± 17.9 192.2 ± 19.2 621.5 ± 38.9 350.8 ± 24.8 *** 
Fasting plasma 
insulin (ng/ml) 
0.37 ± 0.17 0.27 ± 0.11 2.6 ± 0.5 2.7 ± 0.6 
Refed plasma 
insulin (ng/ml) 
4.9 ± 0.7 4.5 ± 0.8 16.2 ± 4.0 82.6 ± 9.1 *** 
Plasma FFA 
(mM) 
0.81 ± 0.10 0.75 ± 0.04 0.93 ± 0.06 0.74 ± 0.03 ** 
Plasma TG 
(mg/dl) 
75.5 ± 11.7 105.8 ± 11.7 114.8 ± 15.2 69.1 ± 4.0 ** 
Plasma T-Cho 
(mg/dl) 
73.2 ± 7.3 72.5 ± 3.3 141.6 ± 19.2 140.0 ± 24.2 
Plasma ALT 
(Karmen) 
7.22 ± 0.58 10.78 ± 1.36 17.03 ± 3.31 63.00 ± 1.17 
Liver TG 
(mg/g) 
23.6 ± 3.0 26.2 ± 5.2 52.1 ± 4.5 76.8 ± 6.6 ** 
Liver T-Cho 
(mg/g) 
2.8 ± 0.5 2.3 ± 0.1 4.2 ± 0.7 5.3 ± 0.7 
 
Values are presented as means ± SEM.  n = 8–13 per group. BW, body weight, eWAT; epididymal 
white adipose tissue; FFA, free fatty acid; TG, triglyceride; T-Cho, total cholesterol; ALT, alanine 
transaminase. P < 0.01 vs db/db;Elovl6+/+, P < 0.01 vs db/db;Elovl6+/+, P < 0.001 vs 
db/db;Elovl6+/+. 
6  8 10 12 14 16 40 4    8  12  16    40 
Age (weeks) Age (weeks) 
Figure 1. Elovl6 deficiency in db/db mice improves hyperglycemia without affecting obesity. 
 (a) Changes in body weight in db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice at indicated ages 
(n = 5–8). (b, c) Blood glucose (b) and plasma insulin (c) concentrations in db/+;Elovl6+/+, db/+;Elovl6-/-, 
db/db;Elovl6+/+, and db/db;Elovl6-/- mice after 4 h of fasting at indicated ages (n = 10–14). (d) HbA1c levels in 
db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 12 weeks of age (n = 4–11). Data are 
presented as means ± SEM. $ P < 0.05, $$ P < 0.01, $$$ P < 0.001 for db/db;Elovl6+/+ mice as compared to 
db/+;Elovl6+/+ mice. # P < 0.05, ## P < 0.01, ###P < 0.001 for db/db;Elovl6-/- mice as compared to db/+;Elovl6+/+ mice.      
* P < 0.05, ** P < 0.01, *** P < 0.001 for db/db;Elovl6-/- mice as compared to db/db;Elovl6+/+mice. 
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Figure 2. Elovl6 deficiency in db/db mice improves glucose intolerance without affecting insulin sensitivity.  
(a, b) Oral glucose tolerance tests (1 g/kg) were performed on 12-week-old mice after 16 h of fasting. Blood 
glucose (a) and plasma insulin (b) levels in db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice 
(n = 5–8). (c) Blood glucose levels in 8-week-old db/+;Elovl6+/+ and db/+;Elovl6-/- mice administered 
intraperitoneally with insulin (0.5 units/kg) after 4 h of fasting (n = 8). (d) Blood glucose levels in 8-week-old 
db/db;Elovl6+/+ and db/db;Elovl6-/- mice administered intraperitoneally with insulin (2.0 units/kg) after 16 h of 
fasting (n = 9). Data are presented as means ± SEM. $ P < 0.05, $$ P < 0.01, $$$ P < 0.001 for db/db;Elovl6+/+ mice 
as compared to db/+;Elovl6+/+ mice. #P < 0.05, ## P < 0.01, ### P < 0.001 for db/db;Elovl6-/- mice as compared to 
db/+;Elovl6+/+ mice.* P < 0.05, ** P < 0.01, *** P < 0.001 for db/db;Elovl6-/- mice as compared to 
db/db;Elovl6+/+mice. 
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Figure 3. Effect of Elovl6 deficiency on histology and gene expression in liver of db/db mice. 
 (a) Representative hematoxylin and eosin staining in liver sections from db/+;Elovl6+/+, db/+;Elovl6-/-, 
db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 16 weeks of age. (b) Real-time RT-PCR analysis of for db/db;Elovl6-/- 
mice as compared to db/db;Elovl6+/+mice. genes for fatty acid (FA) synthesis, β-oxidation, and glucose 
metabolism in livers of db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 16 weeks of age. 
n = 9–12 per group. Data are presented as means ± SEM. ∗ P < 0.05, ∗∗ P <0.01, ∗∗∗ P < 0.001.  
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Figure 4. Effect of Elovl6 deficiency on histology and gene expression of epididymal white adipose tissue in 
db/db mice.  
(a) Representative hematoxylin and eosin staining in epididymal white adipose tissue (eWAT) sections from 
db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 16 weeks of age. (b) Real-time RT-PCR 
analysis  of  genes for fatty acid (FA) synthesis, glucose uptake, and inflammation in the eWAT of 
db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 16 weeks of age. n =10–12 per group. 
Data are presented as means ± SEM. ∗ P < 0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.  
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Figure 5. Elovl6 deficiency increases pancreatic islet numbers and expands β-cell mass in db/db mice. 
 (a) Pancreatic islets were isolated from db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 12 
weeks of age and counted manually (n = 12–14). (b) Representative images of isolated islets that were visualized by 
microscopy. Scale bars: 100 mm. (c, d) Representative images of pancreatic sections from 16-week-old 
db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice that were stained with hematoxylin and eosin 
(c) or antibodies to insulin (green) and glucagon (red) (d). (e) BrdU-positive cells within islet areas were detected by 
immunohistochemistry, and the proportion of BrdU-positive proliferating cells is shown as percentage of the total 
number of insulin-positive cells in sections. (f) TUNEL staining was performed, and the proportion of TUNEL-
positive cells is shown as percentage of the total number of insulin-positive cells in sections. More than 100 islets 
were counted in each mouse for (e) and (f). Data are presented as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 
0.001. 
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Figure 6. Representative immunostaining images for insulin in pancreatic sections from 
db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 16 weeks of age.  
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Figure 7. Elovl6 deficiency in db/db mice enhances insulin secretion, increases insulin content, and decreases 
triglyceride and oleic acid levels in pancreatic islets. 
 (a) Glucose- or KCl- stimulated insulin secretion in islets isolated from db/+;Elovl6+/+, db/+;Elovl6-/-, 
db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 12 weeks of age. Five isolated islets from each group (six batches in each 
genotype) were incubated in Krebs-Ringer Bicarbonate Hepes (KRBH) buffer containing 1% BSA and either 2.8 mM 
glucose, 20 mM glucose, or 2.8 mM glucose with 30 mM KCl for 30 min, and insulin secretion was measured (n = 4). 
(b) Insulin content in isolated islets from db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 
12 weeks of age (n = 12). (c) Triglyceride (TG) content in isolated islets from db/+;Elovl6+/+, db/+;Elovl6-/-, 
db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 12 weeks of age (n = 12). (d) Fatty acid (FA) composition in isolated 
islets from db/+;Elovl6+/+ (n = 3), db/+;Elovl6-/- (n = 3), db/db;Elovl6+/+ (n = 4), and db/db;Elovl6-/- (n = 4) mice at 12 
weeks of age (n = 3–4). Data are presented as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 8. Plasma fatty acid composition in db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and 
db/db;Elovl6-/- mice at 12 weeks of age. n = 3 per group. Data are presented as means ± SEM. ∗ P < 
0.05, ∗∗ P < 0.01, ∗∗∗ P < 0.001.  
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Figure 9. Effect of Elovl6 deficiency on islet gene expression in db/db mice.  
Real-time RT-PCR analysis to measure mRNA levels of genes involved in fatty acid (FA) metabolism (a), b-
oxidation (b), b-cell function (c), b-cell proliferation and islet regeneration (d), apoptosis (e), inflammation 
(f), and stress response (g) in isolated islets from db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and 
db/db;Elovl6-/- mice at 12 weeks of age (n = 7–8). Expression values were normalized to mRNA levels of 
cyclophilin and are presented as fold-induction compared with control db/+;Elovl6+/+ islets. Data are 
presentend as means ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001. 
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Figure 10. Representative images of immunohistochemical staining for Mac3 in pancreatic section 
form db/+;Elovl6+/+, db/+;Elovl6-/-, db/db;Elovl6+/+, and db/db;Elovl6-/- mice at 16 weeks of age. 
Scale bars: 100 µm.  
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Figure 11. Oleate decreases Pdx1 expression and increases Ccl2 expression and CCL2 secretion in MIN6 
cells.  
Cell viability (a), apoptosis, Cleaved Caspase 3-positive cells within section areas were detected by 
immunohistochemistry, and the proportion of Cleaved Caspase 3 -positive cells is shown as percentage of the total 
number of MIN6 cells in sections. (b), mRNA expression (c), and levels of CCL2 released in supernatants (d) of 
MIN6 cells cultured for 24 h in the presence of the indicated FAs or under control conditions (n = 8). Data are 
shown as mean ± SEM. * P < 0.05, ** P < 0.01, *** P < 0.001 for experimental MIN6 cell as compared with their 
respective controls. 
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Figure 12. Elovl6 modified FA composition and attenuated b-cell dysfunction to prevent T2D. 
